Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.80 |
| ▸ | MTOR | P42345 | 9/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.70 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.70 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | PAK4 | O96013 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | FGR | P09769 | 1/20 | 0.70 |
| ▸ | FER | P16591 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.70 |
| ▸ | JAK1 | P23458 | 1/20 | 0.70 |
| ▸ | TEC | P42680 | 1/20 | 0.70 |
| ▸ | SYK | P43405 | 1/20 | 0.70 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.70 |
| ▸ | BTK | Q06187 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466240 | 1.00 | PIK3CA (0.80) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16256628 | 0.91 | PIK3CA (0.83) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181268 | 0.89 | PIK3CA (0.63) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL13505680 | 0.89 | PIK3CA (0.62) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181540 | 0.87 | PIK3CA (0.69) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4439427 | 0.86 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4444187 | 0.84 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL466241 | 0.84 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL190335 | 0.84 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1180926 | 0.84 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2405916-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9335320-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2518074-B1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2205242-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130345217-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130330765-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8604014-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8536161-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885MTOR 17/4885PIK3CD 2/4885 |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | PIK3CA, PIK3CD, MCL1 | PIK3CA 1/4885MTOR 33/4885PIK3CD 2/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885MTOR 11/4885PIK3CD 5/4885 |
| US-20130345217-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885MTOR 17/4885PIK3CD 2/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | PIK3CA 9/4885MTOR 8/4885PIK3CD 11/4885 |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885MTOR 11/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.